We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Theravance Bio (TBPH) Down 12.5% Since Last Earnings Report: Can It Rebound?
Read MoreHide Full Article
It has been about a month since the last earnings report for Theravance Biopharma (TBPH - Free Report) . Shares have lost about 12.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Theravance Bio due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Theravance Earnings Miss Estimates in Q3, Revenues In Line
Theravance incurred a loss of $1.16 per share in the reported quarter, wider than the Zacks Consensus Estimate of a loss of 98 cents and the year-ago loss of $1.05 as well.
Total revenues of $18.3 million in the quarter were in line with the Zacks Consensus Estimate. The top line increased 47.6% year over year, mainly on higher revenues from the collaboration agreement with Mylan.
Total revenues comprised collaboration revenues worth $7.3 million from Janssen and $11 million from the collaboration agreement with Mylan in relation to Yupelri.
Quarterly Details
Research & development expenses were $67.4 million, up 29.6% from the year-ago quarter, primarily due to higher external cost pertaining to pipeline development.
Selling, general & administrative expenses rose 7.4% to $27.5 million due to employee-related expenses resulting from higher compensation-related cost.
As of Sep 30, 2020, Theravance had cash, cash equivalents and marketable securities worth $358.3 million compared with $438.3 million as of Jun 30, 2020.
2020 Outlook
The company anticipates operating loss (excluding non-cash share-based compensation) in the range of $225-$235 million, higher than the earlier projection of $205-$225 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month. The consensus estimate has shifted -19.02% due to these changes.
VGM Scores
Currently, Theravance Bio has a poor Growth Score of F, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Theravance Bio has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Theravance Bio (TBPH) Down 12.5% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Theravance Biopharma (TBPH - Free Report) . Shares have lost about 12.5% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Theravance Bio due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts.
Theravance Earnings Miss Estimates in Q3, Revenues In Line
Theravance incurred a loss of $1.16 per share in the reported quarter, wider than the Zacks Consensus Estimate of a loss of 98 cents and the year-ago loss of $1.05 as well.
Total revenues of $18.3 million in the quarter were in line with the Zacks Consensus Estimate. The top line increased 47.6% year over year, mainly on higher revenues from the collaboration agreement with Mylan.
Total revenues comprised collaboration revenues worth $7.3 million from Janssen and $11 million from the collaboration agreement with Mylan in relation to Yupelri.
Quarterly Details
Research & development expenses were $67.4 million, up 29.6% from the year-ago quarter, primarily due to higher external cost pertaining to pipeline development.
Selling, general & administrative expenses rose 7.4% to $27.5 million due to employee-related expenses resulting from higher compensation-related cost.
As of Sep 30, 2020, Theravance had cash, cash equivalents and marketable securities worth $358.3 million compared with $438.3 million as of Jun 30, 2020.
2020 Outlook
The company anticipates operating loss (excluding non-cash share-based compensation) in the range of $225-$235 million, higher than the earlier projection of $205-$225 million.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month. The consensus estimate has shifted -19.02% due to these changes.
VGM Scores
Currently, Theravance Bio has a poor Growth Score of F, a grade with the same score on the momentum front. Following the exact same course, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. Notably, Theravance Bio has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.